Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel ...

As of Friday, January 09, Rigel Pharmaceuticals, Inc.’s RIGL share price has dipped by 5.01%, which has investors questioning ...

Onco360®, the nation’s leading independent specialty pharmacy, has been chosen by Rigel Pharmaceuticals as limited ...

Rigel Pharmaceuticals reported promising preliminary Q4 and full-year 2023 results, with record-breaking net product sales for TAVALISSE and REZLIDHIA. The company's cash position remains healthy, ...

Rigel Pharmaceuticals RIGL will release its quarterly earnings report on Tuesday, 2025-08-05. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Rigel Pharmaceuticals ...

CEO Raul Rodriguez highlighted "year-over-year net product sales growth of 68%" and total revenue of $53.3 million for Q1 2025. He noted that Rigel achieved $11.4 million in net income for the quarter ...

(RTTNews) - Shares of Rigel Pharmaceuticals, Inc. (RIGL) are slipping over 11% in extended session on Monday after the company said it has received guidance from the U.S. Food and Drug ...

Registrational Phase 2 data demonstrate olutasidenib's potential as a market-leading, oral, mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor for the treatment of relapsed or refractory acute ...

Raymond (NSE:RYMD) J. Furey, the Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary at Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), recently sold shares of the ...

While Rigel is still determining final results for the fourth quarter of 2024, the company expects to report fourth quarter total revenue of $57.6M, compared to $35.8M for the same period of 2023.

Rigel Pharmaceuticals (NASDAQ:RIGL) is gearing up to announce its quarterly earnings on Tuesday, 2025-11-04. Here's a quick overview of what investors should know before the release. Analysts are ...

Dec 1 (Reuters) - Rigel Pharmaceuticals (RIGL.O), opens new tab said on Thursday the U.S. health regulator has approved its drug for the treatment of patients with a type of leukemia, sending its ...